Cover Image
市場調查報告書

下一代癌症診斷市場預測 (2017-2027年):次世代定序(NGS),微陣列,循環腫瘤細胞 (CTC) 分析,In Situ雜合反應(ISH),高度PCR技術

Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques

出版商 Visiongain Ltd 商品編碼 336178
出版日期 內容資訊 英文 166 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
下一代癌症診斷市場預測 (2017-2027年):次世代定序(NGS),微陣列,循環腫瘤細胞 (CTC) 分析,In Situ雜合反應(ISH),高度PCR技術 Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques
出版日期: 2017年05月10日 內容資訊: 英文 166 Pages
簡介

下一代癌症診斷的全球市場,預計在調查期間前半以16.5%,後半以19.1%的年複合成長率擴大,從2016年的19億美元成長到2021年的41億美元規模。

本報告提供全球下一代癌症診斷市場相關調查,癌症診斷技術及技術類型和概要,市場整體主要趨勢及成長預測,各檢驗/技術區分、地區/主要國家趨勢與市場規模的變化與預測,主要企業簡介,產品,配合措施,SWOT分析等彙整資料。

第1章 報告概要

第2章 下一代癌症診斷概要

  • 癌症是什麼
  • 癌症診斷概要
    • 篩檢
    • 診斷
    • 癌症分期
  • 癌症診斷技術
    • 身體檢查
    • 影像技術
    • 組織病理學 、細胞學性檢驗
    • 免疫組織化學 (IHC) 分析
    • 循環腫瘤細胞 (CTC) 分析
    • 分子診斷、IVD
  • 遺傳性、後天性遺傳基因突變檢驗
  • 搭配診斷 (CDx)
  • 藥事未核准檢驗 (LDT:Laboratory Developed Test)
  • Precision Medicine
  • 政府的法律規章
    • 美國
    • EU
  • 市場定義

第3章 全球下一代癌症診斷市場預測

  • 全球下一代癌症診斷市場:概要
  • 全球下一代癌症診斷市場預測
  • 各部門佔有率的變化的預測
  • 生物標記、分子診斷
    • 乳癌
    • 前列腺癌
    • 直腸癌
  • 搭配診斷和2個產業的合作
  • 替換已通過核准檢驗的LDT
  • 診斷檢驗的分散化
  • 下一代癌症診斷:成長推動因素、阻礙要素

第4章 下一代癌症診斷的次級市場

  • 先進PCR技術
    • 市場預測
    • 即時PCR市場主要產品
    • 數位PCR市場主要產品
    • 被PCR化驗替換的子宮頸抹片檢查
    • 成長推動因素、阻礙要素
  • In Situ雜合反應 (ISH)
    • 市場預測
    • ISH癌症診斷市場主要產品
    • 乳癌的HER2檢驗
    • 成長推動因素、阻礙要素
  • 循環腫瘤細胞 (CTC) 分析
    • 市場預測
    • 循環腫瘤細胞 (CTC)分析市場主要產品
    • Epic Sciences、LabCorp:亞洲市場的擴張
    • CTC的超音波的分離
    • CTC叢集:轉移的原因?
    • 成長推動因素、阻礙要素
  • 微陣列
    • 市場預測
    • 微陣列市場主要產品
    • 趨勢、開發情形
    • 成長推動因素、阻礙要素
  • 次世代定序 (NGS)
    • 市場預測
    • 次世代定序 (NGS) 市場主要產品
    • 趨勢、開發情形
    • 成長推動因素、阻礙要素

第5章 主要國家市場預測

  • 全球下一代癌症診斷市場預測:各地區
  • 美國
  • 歐盟5國
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
  • 日本
  • 中國
  • 印度
  • 巴西
  • 俄羅斯

第6章 主要企業

  • Roche Diagnostics
  • Abbott Laboratories
  • Qiagen
  • Thermo Fisher Scientific
  • Agilent Technologies
  • Hologic
  • Illumina
  • Myriad Genetics

第7章 定性分析、預測

  • SWOT分析

第8章 總論

  • 全球下一代癌症診斷市場
  • 下一代癌症診斷的未來

詞彙表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0192

The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021.

While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.

Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 166-page report you will receive 87 charts - all unavailable elsewhere.

The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.
  • 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
    • Advanced PCR Techniques
    • In Situ Hybridization (ISH)
    • Circulating Tumour Cells (CTCs) Analysis
    • Microarray
    • Next-Generation Sequencing (NGS)
  • Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
    • US
    • EU5
    • Japan
    • China
    • India
    • Brazil
    • Russia
    • Rest of the World
  • Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
    • Roche Diagnostics
    • Abbott Laboratories
    • Qiagen
    • Thermo Fisher Scientific
    • Agilent Technologies
    • Hologic
    • Illumina
    • Myriad Genetics
  • SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Findings
  • 1.2. Structure of the Report
  • 1.3. Global Next-Generation Cancer Diagnostics Market Segmentation
  • 1.4. Why You Should Read This Report
  • 1.5. How This Report Delivers
  • 1.6. Key Questions Answered by This Analytical Report
  • 1.7. Who is This Report For?
  • 1.8. Methodology
  • 1.9. Frequently Asked Questions (FAQ)
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics

  • 2.1. What Is Cancer?
  • 2.2. Cancer Diagnostics: An Overview
    • 2.2.1. Screening
    • 2.2.2. Diagnosis
    • 2.2.3. Staging
  • 2.3. Cancer Diagnosis Methods
    • 2.3.1. Physical Examination
    • 2.3.2. Imaging Techniques
    • 2.3.3. Histopathological and Cytological Techniques
    • 2.3.4. Immunohistochemistry (IHC) Analysis
    • 2.3.5. Circulating Tumour Cell (CTC) Analysis
    • 2.3.6. Molecular Diagnostics and IVD
  • 2.4. Tests for Inherited and Acquired Genetic Mutations
  • 2.5. Companion Diagnostics (CDx)
  • 2.6. Laboratory Developed Test (LDT)
  • 2.7. Precision Medicine
  • 2.8. Government Regulations
    • 2.8.1. The US Approval and Regulation System
    • 2.8.2. The EU Approval and Regulation System
  • 2.9. Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2016-2027

  • 3.1. The Global Next-Generation Cancer Diagnostics Market: Overview
  • 3.2. The Global Next-Generation Cancer Diagnostics Market Forecast 2016-2027
  • 3.3. How Will Segmental Market Shares Change to 2027?
  • 3.4. Biomarkers and Molecular Diagnostics
    • 3.4.1. Biomarkers and Diagnostic Tests for Breast Cancer
    • 3.4.2. Biomarkers and Diagnostic Tests for Prostate Cancer
    • 3.4.3. Biomarkers and Diagnostic Tests for Colorectal Cancer
  • 3.5. Companion Diagnostics and Collaborations between Two Industries
  • 3.6. LDTs to be Replaced by Approved Tests
  • 3.7. Decentralisation of Diagnostic Tests
  • 3.8. Next-Generation Cancer Diagnostics: Drivers and Restraints 2017-2027

4. Next-Generation Cancer Diagnostics Submarkets 2017-2027

  • 4.1. Advanced PCR Techniques
    • 4.1.1. Advanced PCR Techniques Market Forecast 2016-2027
    • 4.1.2. Leading Products in the Real-Time PCR Market
    • 4.1.3. Leading Products in the Digital PCR Market
    • 4.1.4. Pap Tests Being Replaced by PCR Assays
    • 4.1.5. Advanced PCR-Based Techniques: Drivers and Restraints 2017-2027
  • 4.2. In Situ Hybridization (ISH)
    • 4.2.1. ISH Cancer Diagnostics Market Forecast 2016-2027
    • 4.2.2. Leading Products in the ISH Cancer Diagnostics Market
    • 4.2.3. HER2 Tests for Breast Cancer
    • 4.2.4. ISH Cancer Diagnostics: Drivers and Restraints 2017-2027
  • 4.3. Circulating Tumour Cells (CTCs) Analysis
    • 4.3.1. CTCs Analysis Market Forecast 2016-2027
    • 4.3.2. Leading Product in the CTCs Analysis Market
    • 4.3.3. Epic Sciences and LabCorp to Expand in Asia Markets
    • 4.3.4. CTCs Separation by Ultrasound
    • 4.3.5. CTC Clusters More Likely to Cause Metastasis?
    • 4.3.6. CTCs Analysis: Drivers and Restraints 2017-2027
  • 4.4. Microarray
    • 4.4.1. Microarray Cancer Diagnostics Market Forecast 2016-2027
    • 4.4.2. Leading Products in the Microarray Market
    • 4.4.3. Microarray Cancer Diagnostics: Trends and Developments
    • 4.4.4. Microarray Cancer Diagnostics: Drivers and Restraints 2017-2027
  • 4.5. Next-Generation Sequencing (NGS)
    • 4.5.1. NGS Cancer Diagnostics Market Forecast 2016-2027
    • 4.5.2. Leading Products in the NGS Market
    • 4.5.3. NGS Cancer Diagnostics: Trends and Developments
    • 4.5.4. NGS Cancer Diagnostics: Drivers and Restraints 2017-2027

5. Leading National Markets 2017-2027

  • 5.1. World Next-Generation Cancer Diagnostics Market: Regional Forecast 2017-2027
    • 5.1.1. How Will Regional Market Shares Change to 2027?
  • 5.2. US Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.2.1. FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
    • 5.2.2. Obama Launched 'Precision Medicine Initiative'
  • 5.3. EU5. Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.3.1. Germany: Leading Market in the EU
    • 5.3.2. France: Reduction in Healthcare Spending
    • 5.3.3. UK: 100,000 Genomes Project
    • 5.3.4. Spain: Recovering from Financial Crisis
    • 5.3.5. Italy: Decreasing Reimbursement
  • 5.4. Japanese Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.4.1. Takeda Collaborated with NCC in Genomic Screening Project
    • 5.4.2. Qiagen Partnered Hitachi on PCR and NGS Technologies
    • 5.4.3. Increase Cancer Rates in Fukushima after Nuclear Disaster?
  • 5.5. Chinese Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.5.1. Illumina Entering the Chinese Market
    • 5.5.2. Epigenomics Colorectal Cancer Test Approved in China
    • 5.5.3. China Offered Free Screenings for Cervical and Breast Cancer
  • 5.6. Indian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.6.1. Lack of Genetic Testing Regulation
    • 5.6.2. Cancer Genetics Launched NGS Cancer Panel in India
  • 5.7. Brazilian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
  • 5.8. Russian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.8.1. IBM's Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2017

  • 6.1. Roche Diagnostics
    • 6.1.1. Roche Diagnostics: Product Portfolio
    • 6.1.2. Roche Diagnostics: Diagnostics Sales Outlook
    • 6.1.3. Cobas HPV Test Approved in the US in 2014
    • 6.1.4. Roche Diagnostics: Recent M&A Activity
    • 6.1.5. Roche Coming Back to the NGS Business?
  • 6.2. Abbott Laboratories
    • 6.2.1. Abbott: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.2.2. Abbott: Diagnostics Sales Outlook
    • 6.2.3. Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
  • 6.3. Qiagen
    • 6.3.1. Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2017
    • 6.3.2. Qiagen: Diagnostics Sales Outlook
    • 6.3.3. HalioDx Created from Qiagen Marseille
  • 6.4. Thermo Fisher Scientific
    • 6.4.1. Thermo Fisher Scientific: Business Segments
    • 6.4.2. Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
    • 6.4.3. Thermo Fisher: Life Sciences Outlook
    • 6.4.4. NGS Oncomine Focus Assay for Oncology Research
  • 6.5. Agilent Technologies
    • 6.5.1. Agilent: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.5.2. Agilent: Life Sciences and Diagnostics Sales Outlook
    • 6.5.3. Partnerships and Collaborations for Companion Diagnostics
  • 6.6. Hologic
    • 6.6.1. Hologic: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.6.2. Hologic: Diagnostics Sales Outlook
  • 6.7. Illumina
    • 6.7.1. Illumina: Technology and Product Portfolio
    • 6.7.2. Illumina: Sales Outlook
    • 6.7.3. Illumina: Recent M&A Activity
    • 6.7.4. Joined Forces with UK Government for 100,000 Genomes Project
    • 6.7.5. Partnered with Merck Serono to Develop NGS Cancer Diagnostics
    • 6.7.6. Investing on Synthetic DNA Manufacturing Technology
  • 6.8. Myriad Genetics
    • 6.8.1. Myriad: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.8.2. Myriad: Sales Outlook
    • 6.8.3. New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2017-2027

  • 7.1. SWOT Analysis of the Next-Generation Cancer Diagnostics Market
  • 7.2. Strengths
    • 7.2.1. Global Cancer Rates Set to Soar
    • 7.2.2. Increasing Awareness of Molecular Cancer Diagnostics
    • 7.2.3. The Trend in Precision Medicine
  • 7.3. Weaknesses
    • 7.3.1. Industry Facing Increasing Reimbursement Pressure
    • 7.3.2. Physicians' Reliance on Traditional Methods
  • 7.4. Opportunities
    • 7.4.1. Expanding Biomarkers and Cancer Test Menus
    • 7.4.2. Emerging Market to Provide Future Growth
    • 7.4.3. Companion Diagnostics on the Rise
  • 7.5. Threats
    • 7.5.1. Decreasing Healthcare Spending
    • 7.5.2. Gene Patenting Banned in the US?

8. Conclusions

  • 8.1. The World Next-Generation Cancer Diagnostics Market
    • 8.1.1. Current Leading Next-Generation Cancer Diagnostics Segments
    • 8.1.2. Notable Next-Generation Cancer Diagnostics Companies
    • 8.1.3. Leading Regional Markets
    • 8.1.4. World Next-Generation Cancer Diagnostics Market Forecast 2017-2027
  • 8.2. The Future of the Next-Generation Cancer Diagnostics Market
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: New Cancer Cases and Deaths in More Developed and Less Developed Regions
  • Figure 1.2: Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2017
  • Figure 3.1: Most Common Causes of Cancer Death, 2012
  • Figure 3.2: The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 3.3: Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2016
  • Figure 3.4: Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2021
  • Figure 3.5: Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2027
  • Figure 3.6: Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2017-2027
  • Figure 4.1: Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.2: Advanced PCR-Based Techniques: Drivers and Restraints 2017-2027
  • Figure 4.3: ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.4: ISH Cancer Diagnostics: Drivers and Restraints 2017-2027
  • Figure 4.5: CTCs Analysis Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.6: CTCs Analysis: Drivers and Restraints 2017-2027
  • Figure 4.7: Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.8: Microarray Cancer Diagnostics: Drivers and Restraints 2017-2027
  • Figure 4.9: NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.10: NGS Cancer Diagnostics: Drivers and Restraints 2017-2027
  • Figure 5.1: New Cancer Cases and Deaths in More Developed and Less Developed Regions
  • Figure 5.2: World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2016-2027
  • Figure 5.3: World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2016
  • Figure 5.4: World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2021
  • Figure 5.5: World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2027
  • Figure 5.6: US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.7: EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.8: Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.9: Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.10: Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.11: Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.12: Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 6.1: Roche Diagnostics: Revenue Share (%) by Segment, 2016
  • Figure 6.2: Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.3: Roche Diagnostics: Net Sales ($bn) by Region, 2016
  • Figure 6.4: Abbott: Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.5: Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.6: Life Technologies: Revenue ($m), AGR (%), 2008-2012
  • Figure 6.7: Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.8: Hologic: Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.9: Illumina: Revenue Share (%) by Business Segment, 2016
  • Figure 6.10: Illumina: Revenue Share (%) by Geographic Area, 2016
  • Figure 6.11: Illumina: Revenue ($m), AGR (%), 2011-2016
  • Figure 6.12: Myriad: Revenue ($m), AGR (%), 2011-2016

List of Tables

  • Table 1.1: Leading National Next-Generation Cancer Diagnostics Market Forecast 2016-2027 ($m, AGR%, CAGR%)
  • Table 3.1: The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2017-2027
  • Table 3.2: Selected Biomarkers For Cancer Diagnostics
  • Table 3.3: FDA Approved Nucleic Acid Based Tests
  • Table 3.4: Selected Molecular Diagnostic Tests for Breast Cancer
  • Table 3.5: Selected Molecular Diagnostic Tests for Prostate Cancer
  • Table 3.6: Selected Molecular Diagnostics Test for Colorectal Cancer
  • Table 3.7: Companion Diagnostic Devices Approved by FDA
  • Table 4.1: Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.2: ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.3: CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.4: Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.5: NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.1: World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2017-2027
  • Table 5.2: US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3: EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.4: Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.5: Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.6: Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.7: Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.8: Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.1: Roche: Overview
  • Table 6.2: Roche Diagnostics: Key Instrument/Device Launches Planned
  • Table 6.3: Roche Diagnostics: Key Test Launches
  • Table 6.4: Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.5: Abbott Laboratories: Overview
  • Table 6.6: Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.7: Qiagen: Overview
  • Table 6.8: Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.9: Thermo Fisher: Overview
  • Table 6.10: Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2015
  • Table 6.11: Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
  • Table 6.12: Agilent: Overview
  • Table 6.13: Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.14: Hologic: Overview
  • Table 6.15: Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.16: Illumina: Overview
  • Table 6.17: Illumina: Sequencing Product Portfolio
  • Table 6.18: Illumina: Microarray Product Portfolio
  • Table 6.19: Illumina: Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.20: Myriad: Overview
  • Table 6.21: Myriad: Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 7.1: SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2017-2027

Companies Listed

  • 454 Life Sciences
  • Abbott Laboratories
  • AbbVie
  • AbVitro
  • Advanced Cell Diagnostics
  • Advanced Liquid Logic
  • Affymetrix
  • Agendia
  • Agilent Technologies
  • Ambry
  • Amgen
  • Annoroad
  • Applied Biosystems
  • ARCH Venture Partners
  • AstraZeneca
  • Atossa Genetics
  • AvanSci
  • Aviva Biosciences
  • BD
  • Berry Genomics
  • BGI
  • Bina Technologies
  • Biobase
  • Biochain
  • BioFluidica
  • BioMarin Pharmaceutical
  • bioMérieux
  • Bio-Rad
  • BioServe India
  • BlueGnome
  • Bristol-Myers Squibb
  • Bruker
  • Cancer Genetics
  • Cepheid
  • CLC bio
  • CompanionDx
  • Counsyl
  • Crescendo Bioscience
  • CytoTrack
  • Dako
  • DakoCytomation
  • Danaher
  • DiagnoCure
  • DxS
  • Eli Lilly
  • Enzymatics
  • Epic Sciences
  • Epicentre Technologies
  • Epigenomics
  • Exact Sciences
  • Fidelity Management
  • Fluidigm
  • Fluxion
  • GeneDx
  • Genentech
  • Genia Technologies
  • Genomic Health
  • Gen-Probe
  • GnuBio
  • HalioDX
  • Hitachi High-Technologies
  • Hologic
  • Idaho Technology
  • IGEN International
  • Illumina
  • Ingenuity Systems
  • Insilico Medicine
  • Invitae
  • Invitrogen
  • Ipsogen
  • Iquum
  • Iris Molecular Diagnostics
  • Janssen Biotech
  • Janssen Diagnostics
  • LabCorp
  • Life Technologies
  • Luminex Corporation
  • Manostring Technologies
  • Merck
  • Miltenyi Biotec
  • Mylan
  • Myraqa
  • Myriad Genetics
  • NextBio
  • Oncolys BioPharma
  • Ono Pharmaceutical
  • Oxford Nanopore
  • Pacific Biosciences
  • Pathway Genomics
  • Pathway Pharmaceuticals
  • Pensabio
  • PerkinElmer
  • Pfizer
  • Prosigna
  • Qiagen
  • Qiagen Marseille
  • Quest Diagnostics
  • Quidel
  • RainDance Technologies
  • Rarecells
  • Roche Diagnostics
  • Sakura
  • Sanofi
  • ScreenCell
  • Siemens
  • Signature Diagnostics
  • Silicon Biosystems
  • SRI Biosciences
  • Stratos Genomics
  • Sysmex
  • Takeda
  • Thermo Fisher Scientific
  • Twist Bioscience
  • Ventana Medical Systems
  • Verinata Health
  • Vysis

List of Organizations Mentioned in the Report

  • Actionable Genome Consortium
  • Arizona State University
  • Carnegie Mellon University
  • First Oncology Research and Advisory Center
  • Genomics England
  • Institut Curie
  • MGH Cancer Center
  • Massachusetts Institute of Technology
  • National Cancer Center
  • Paris-Descartes University
  • Pennsylvania State University
Back to Top